HEPA vs. LPTX, MEIP, PRPH, GELS, ME, RLMD, TRIB, SYBX, ERNA, and MRKR
Should you be buying Hepion Pharmaceuticals stock or one of its competitors? The main competitors of Hepion Pharmaceuticals include Leap Therapeutics (LPTX), MEI Pharma (MEIP), ProPhase Labs (PRPH), Gelteq (GELS), 23andMe (ME), Relmada Therapeutics (RLMD), Trinity Biotech (TRIB), Synlogic (SYBX), Eterna Therapeutics (ERNA), and Marker Therapeutics (MRKR). These companies are all part of the "pharmaceutical products" industry.
Hepion Pharmaceuticals vs.
Leap Therapeutics (NASDAQ:LPTX) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
30.5% of Leap Therapeutics shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 5.4% of Leap Therapeutics shares are held by insiders. Comparatively, 4.7% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Leap Therapeutics received 273 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. Likewise, 68.37% of users gave Leap Therapeutics an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote.
In the previous week, Leap Therapeutics had 7 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 7 mentions for Leap Therapeutics and 0 mentions for Hepion Pharmaceuticals. Leap Therapeutics' average media sentiment score of 1.01 beat Hepion Pharmaceuticals' score of 0.00 indicating that Leap Therapeutics is being referred to more favorably in the media.
Leap Therapeutics currently has a consensus price target of $4.92, suggesting a potential upside of 1,260.45%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Leap Therapeutics is more favorable than Hepion Pharmaceuticals.
Leap Therapeutics' return on equity of -116.24% beat Hepion Pharmaceuticals' return on equity.
Leap Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
Leap Therapeutics is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Leap Therapeutics beats Hepion Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
Get Hepion Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hepion Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:HEPA) was last updated on 5/22/2025 by MarketBeat.com Staff
